NCT00693719View on ClinicalTrials.gov

Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

May 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

Etoposide

50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle

DRUG

Irinotecan hydrochloride

Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle

Trial Locations (1)

85724-5024

Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER

NCT00693719 - Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter